Biogen to Present 96-Week Data From Diranersen Alzheimer’s Trial at CTAD 2026

Bitget2026/10/29 11:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Biogen will present new Alzheimer’s disease study data at CTAD in Boston, November 16-19, 2026.
Investigational diranersen’s Phase 2 CELIA update will cover longer-term efficacy, safety and biomarkers, building on results presented in July 2026.
Leqembi presentations will examine five-year treatment outcomes and safety, alongside three-year real-world evidence on maintenance therapy and at-home subcutaneous administration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biogen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610290659PRIMZONEFULLFEED9855736) on October 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Biogen to Present 96-Week Data From Diranersen Alzheimer’s Trial at CTAD 2026

You may also like

Crypto prices